Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections

American Journal of Health-System Pharmacy

Volumn 72, Issue 21, 2015, Pages 1871-1875

  Jacobson, Shauna M ^a   Slain, Douglas ^b  

^a ORLANDO REGIONAL MEDICAL CENTER   (United States)

^b WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ATLAS SCORE; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC ACCURACY; DRUG SUBSTITUTION; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT INFECTION; RISK FACTOR; SCORING SYSTEM; AGED; CLOSTRIDIUM INFECTIONS; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; POINT OF CARE TESTING; PREDICTIVE VALUE; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FEMALE; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; POINT-OF-CARE TESTING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84962791668     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp150076     Document Type: Article

References (13)

1. McDonald EG, Milligan J, Frenette C, Lee TC. JAMA Intern Med. 2015; 175:784-91.
2. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353:2442-9.
3. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45:302-7.
4. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55.
5. Chopra T, Miller M, Severson R et al. ATLAS-a bedside scoring system-predicting mortality due to Clostridium difficile infection (CDI) in elderly hospitalized patients. https://idsa.confex.com/idsa/2010/webprogram/Paper4263.html (accessed 2015 Jul 27).
6. Miller MA, Louie T, Mullane K et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013; 13:148.
7. Kamobj M, Khosa P, Kaltas A et al. Relapse versus reinfection: surveillance of Clostridium difficile infection. Clin Infect Dis. 2011; 53:1003-6.
8. Garey KW, Ghantoji SS, Shah DN et al. A randomized, double-blind, placebocontrolled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother. 2011; 66:2850-5.
9. Mullane K, Miller M, Weiss K et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011; 53:440-7.
10. Bauer MP, Hensgens MP, Miller MA et al. Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. Clin Infect Dis. 2012; 55(suppl 2):S149-53.
11. Mulherin DW, Hutchison AM, Thomas GJ et al. Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection. 2014; 42:999-1005.
12. Byker GL, Dinh MT, Gunaratnam NT et al. Management of Clostridium difficile infection: survey of practices and compliance with national guidelines among primary care physicians. Infect Control Hosp Epidemiol. 2009; 30:397-9.
13. Cho J, Sharma R, Armitstead J et al. Utilization of a clinical bedside scoring system (ATLAS) to determine treatment regimens for patients with Clostridium difficile-associated diarrhea. Abstract presented at 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2014 Sep 5-9.